| Product Unit Size | Cost | Quantity | Stock |
|---|
PIK-75 is a selective inhibitor of p110α, an isoform of PI3K. When combined with gemcitabine, PIK-75 reduced NRF2 protein levels, augmenting the antitumor effect of gemcitabine in human pancreatic cancer cell lines. PIK-75 was chosen over several other PI3K/Akt pathway inhibitors and used with the Braf inhibitor vemurafenib in models of advanced melanoma.
| Cas No. | 372196-67-3 |
|---|---|
| Purity | ≥99% |
| Formula | C16H14BrN5O4S |
| Formula Wt. | 452.28 |
| Chemical Name | PIK-75 |
| IUPAC Name | N'-[(E)-(6-Bromoimidazo[1,2-a]pyridin-3-yl)methylene]-N,2-dimethyl-5-nitrobenzenesulfonohydrazide |
| Synonym | PIK 75, PIK75 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Duong H., Yi Y., et al. Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. Int J Oncol. 44(3):959-69 (2014). PMID: 2436609.
Pedini F., De Luca G., et al. Joint action of miR-126 and MAPK/PI3K inhibitors against metastatic melanoma. Mol Oncol. 2019. PMID: 31115969.